Thang H. Nguyen

Array ( [id] => 20497748 [patent_doc_number] => 20260027205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-29 [patent_title] => STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/346638 [patent_app_country] => US [patent_app_date] => 2025-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34941 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19346638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20497747 [patent_doc_number] => 20260027204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-29 [patent_title] => STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/346623 [patent_app_country] => US [patent_app_date] => 2025-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34830 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19346623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265400 [patent_doc_number] => 20240209099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => NOVEL ANTI-HVEGFR2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/555341 [patent_app_country] => US [patent_app_date] => 2022-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18555341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265381 [patent_doc_number] => 20240209080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => FOLR1 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/554745 [patent_app_country] => US [patent_app_date] => 2022-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432544 [patent_doc_number] => 20240301042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => SELECTIVE TARGETING OF OLIGOMERIC B-AMYLOID [patent_app_type] => utility [patent_app_number] => 18/283697 [patent_app_country] => US [patent_app_date] => 2022-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33294 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18283697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172512 [patent_doc_number] => 20240158486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/550214 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7174 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18550214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20594640 [patent_doc_number] => 12578348 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-17 [patent_title] => Blood indicators of Alzheimer's disease [patent_app_type] => utility [patent_app_number] => 17/665057 [patent_app_country] => US [patent_app_date] => 2022-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 4532 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17665057 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776561 [patent_doc_number] => 20220242910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => AGONIST OF SPEXIN-BASED GALANIN TYPE 2 RECEPTOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/579463 [patent_app_country] => US [patent_app_date] => 2022-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17579463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18939662 [patent_doc_number] => 20240034801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => ANTI-PD-L1/ANTI-4-1BB NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMERIC FORM BISPECIFIC ANTIBODY AND PREPARATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/260435 [patent_app_country] => US [patent_app_date] => 2022-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14369 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18260435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17687695 [patent_doc_number] => 20220194987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => BK CHANNEL-MODULATING PEPTIDES AND THEIR USE [patent_app_type] => utility [patent_app_number] => 17/568619 [patent_app_country] => US [patent_app_date] => 2022-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26230 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 179 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17568619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720451 [patent_doc_number] => 20220213171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => Ciliary Neurotrophic Factor Receptor Ligand-Binding Agents and Methods of Using the Same [patent_app_type] => utility [patent_app_number] => 17/556522 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16473 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17556522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520538 [patent_doc_number] => 20220106387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => ANTIBODIES TO PYROGLUTAMATE AMYLOID-B AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/554461 [patent_app_country] => US [patent_app_date] => 2021-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20421 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17554461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17628515 [patent_doc_number] => 20220163530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => TEST KITS, DEVICES AND METHODS FOR DETECTING INFECTION [patent_app_type] => utility [patent_app_number] => 17/535029 [patent_app_country] => US [patent_app_date] => 2021-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6552 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17535029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17596961 [patent_doc_number] => 20220146535 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => COMPOUNDS AND METHODS TARGETING HUMAN TAU [patent_app_type] => utility [patent_app_number] => 17/535059 [patent_app_country] => US [patent_app_date] => 2021-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12107 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17535059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748232 [patent_doc_number] => 20220226435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => Ciliary Neurotrophic Factor Receptor Ligands and Methods of Using the Same [patent_app_type] => utility [patent_app_number] => 17/531439 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17749 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399608 [patent_doc_number] => 20220041698 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => Monoclonal Antibodies Against Pathological Alpha-Synuclein, and Methods Using Same [patent_app_type] => utility [patent_app_number] => 17/509970 [patent_app_country] => US [patent_app_date] => 2021-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11595 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17509970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17736336 [patent_doc_number] => 20220221795 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => METHODS FOR DETECTING TRAUMATIC BRAIN INJURY [patent_app_type] => utility [patent_app_number] => 17/499777 [patent_app_country] => US [patent_app_date] => 2021-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27317 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17499777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503281 [patent_doc_number] => 20220096383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => LYOPHILIZED FORMULATION OF TAT-NR2B9C WITH ACETYLATION SCAVENGER [patent_app_type] => utility [patent_app_number] => 17/473568 [patent_app_country] => US [patent_app_date] => 2021-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17473568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17571107 [patent_doc_number] => 11319365 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-03 [patent_title] => Antibodies that bind to pathological Tau species and uses thereof [patent_app_type] => utility [patent_app_number] => 17/472212 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 38455 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17814335 [patent_doc_number] => 11419924 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => Immunotherapeutic compositions for the treatment of Alzheimer's disease [patent_app_type] => utility [patent_app_number] => 17/467369 [patent_app_country] => US [patent_app_date] => 2021-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 8600 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17467369 [rel_patent_id] =>[rel_patent_doc_number] =>)